Posted by Michael Wonder on 28 Feb 2023
Biologics license application for lecanemab designated for priority review by China NMPA
28 February 2023 - Eisai and Biogen announced today that the biologics license application for lecanemab (brand name in the US: Leqembi), an investigational anti-amyloid beta protofibril antibody, has been designated for priority review by the NMPA in China.
In China, Eisai initiated submission of data for the biologics license application to the NMPA in December 2022.
